Dr. Richard L. Bakst

Claim this profile

Mount Sinai Hospital

Studies Squamous Cell Carcinoma
Studies Head and Neck Cancers
4 reported clinical trials
9 drugs studied

Area of expertise

1

Squamous Cell Carcinoma

Richard L. Bakst has run 2 trials for Squamous Cell Carcinoma. Some of their research focus areas include:

Stage IV
Stage I
Stage II
2

Head And Neck Cancers

Richard L. Bakst has run 2 trials for Head and Neck Cancers. Some of their research focus areas include:

Stage IV
Stage I
Stage II

Affiliated Hospitals

Image of trial facility.

Mount Sinai Hospital

Image of trial facility.

Icahn School Of Medicine At Mount Sinai

Clinical Trials Richard L. Bakst is currently running

Image of trial facility.

Pembrolizumab + Radiation vs Chemotherapy + Radiation

for Head and Neck Cancer

This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \[cisplatin and carboplatin\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Carboplatin is also in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab alone after surgery may work better than the usual approach in shrinking recurrent or primary head and neck squamous cell carcinoma.

Recruiting

1 award

Phase 2

31 criteria

Image of trial facility.

Low-Dose Radiotherapy

for Multiple Myeloma with Bone Pain

This phase II trial studies how well low-dose radiotherapy works in treating bone pain in patients with multiple myeloma that has spread to the bone. Radiation therapy uses high energy x-rays, gamma rays, neutrons, protons, or other sources to kill tumor cells and shrink tumors. Low-dose radiotherapy may be more convenient for patients and their families, may not interfere as much with the timing of chemotherapy, and may have less chance for short term or long-term side effects from the radiation.

Recruiting

1 award

N/A

6 criteria

More about Richard L. Bakst

Clinical Trial Related

4 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Richard L. Bakst has experience with

  • Adjuvant Hypofractionation
  • Definitive Hypofractionation
  • Carboplatin
  • Cisplatin
  • Pembrolizumab
  • Proton Beam Radiation Therapy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Richard L. Bakst specialize in?

Is Richard L. Bakst currently recruiting for clinical trials?

Are there any treatments that Richard L. Bakst has studied deeply?

What is the best way to schedule an appointment with Richard L. Bakst?

What is the office address of Richard L. Bakst?

Is there any support for travel costs?